LTR Pharma (ASX:LTP) has announced that it has received firm commitments to raise $10.5 million before costs to advance the development of its innovative nasal spray treatment for erectile dysfunction.
AusBiotech
New Stories
-
LTR Pharma completes $10.5 million placement to expedite commercialisation of nasal spray
July 25, 2024 - - Latest News -
Remembering Nobel Laureate Professor Robin Warren AC
July 25, 2024 - - AusBiotech -
Orthocell moves ahead on global market expansion with seven new regulatory applications
July 25, 2024 - - Latest News -
Telix completes significant raise that could be used for acquisitions
July 25, 2024 - - Latest News -
Cartherics announces new licensing agreement for innovative cardiac cell therapy
July 25, 2024 - - Latest News -
AusBiotech Early-Stage Innovation Forum opens
July 23, 2024 - - AusBiotech -
Neuren secures Rare Pediatric Disease Designation from FDA
July 23, 2024 - - Latest News